SUNY and NYU will utilize the inhalation technology.

Respironics inked an agreement with The State University of New York (SUNY) and New York University School of Medicine (NYU) to utilize the I-neb Adaptive Aerosol Delivery (AAD®) system for clinical evaluation of aerosolized Interferon Gamma for the treatment of idiopathic pulmonary fibrosis (IPF). The clinical trial will take place over a two-year time period.


The I-neb device uses Respironics’ AAD technology, which reportedly is an “intelligent” inhalation technology that continually monitors and automatically adapts to an individual patient’s breathing pattern to deliver a precise medication dose during the patient’s inhalation phase. The result is precise, reproducible dosing of medication to each patient, regardless of his/her breathing pattern, according to the company.


The I-neb AAD System is Respironics’ third generation AAD System and is smaller, quieter and more portable than earlier product generations, notes a company spokesperson. The device weighs less than eight ounces and can be carried in a purse, pocket or briefcase. The I-neb device also provides audible and visual feedback to the patient informing the patient when the treatment is complete.

Previous articleAbeille Stands to Earn $21M in Deal with SymBio
Next articleCombiMatrix Wins U.S. Air Force Contract to Advance Flu-Detection System